Supply Chain Intelligence

Structure Therapeutics Inc. Supply Chain

GPCR supply chain intelligence for Structure Therapeutics Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

GPCR ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

9Suppliers
18Customers
2Debt Items
20Related Chains

Source-Backed Evidence Depth

Structure Therapeutics Inc. (GPCR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

30Total relationships
4Distinct source URLs
10High confidence
0.742Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Structure Therapeutics Inc. Suppliers

TickerNameConfidenceEvidence
SCHR-DINGER SCHR-DINGER 92% Under the Lhotse-Schrödinger Agreement, Schrödinger is obligated to provide computational modeling and design support, including by using its technology platform to perform virtual screens
GENENTECH GENENTECH 90% The Company granted to GNE a non-exclusive, sublicensable, royalty-bearing license, under the Company’s licensed patents, to make, use, sell, offer for sale, and import licensed products
ROCHE ROCHE 90% The Company granted to GNE a non-exclusive, sublicensable, royalty-bearing license, under the Company’s licensed patents, to make, use, sell, offer for sale, and import licensed products
CANTOR-FITZGERALD-CO CANTOR-FITZGERALD-CO 80% The Amended and Restated Sales Agreement modifies the Sales Agreement to remove the aggregate offering amount of ADSs the Company may offer and sell thereunder
LEERINK-PARTNERS-LLC LEERINK-PARTNERS-LLC 80% The Amended and Restated Sales Agreement modifies the Sales Agreement to remove the aggregate offering amount of ADSs the Company may offer and sell thereunder
CRBP Corbus Pharmaceuticals Holdings, Inc. 72% Reciprocal relationship from CRBP graph: Reciprocal relationship from GPCR graph: Reciprocal relationship from CRBP graph: designed to be an improved next-generation site-specific Nectin-4 targeting …
CTNM Contineum Therapeutics, Inc. 72% Reciprocal relationship from CTNM graph: Reciprocal relationship from GPCR graph: Reciprocal relationship from CTNM graph: Reciprocal relationship from GPCR graph: Reciprocal relationship from CTNM g…
SDGR Schrödinger, Inc. 72% Reciprocal relationship from SDGR graph: Reciprocal relationship from GPCR graph: Reciprocal relationship from SDGR graph: performance-based vesting conditions are considered probable as of that date…
SEPN Septerna, Inc. 72% Reciprocal relationship from SEPN graph: result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated prob…

Structure Therapeutics Inc. Customers

TickerNameConfidenceEvidence
F-HOFFMANN-LA-ROCHE-LTD F-HOFFMANN-LA-ROCHE-LTD 92% Genentech will pay Gasherbrum a one-time, non-refundable payment of $100 million within thirty (30) days after execution of the GNE Agreement.
GENENTECH-INC GENENTECH-INC 92% Genentech will pay Gasherbrum a one-time, non-refundable payment of $100 million within thirty (30) days after execution of the GNE Agreement.
BIOA BioAge Labs, Inc. 72% ould lead to ineffective product or target candidates and exposure to competitive and reputational harm. We face increased competition from other companies that are using AI and related methods for d…
BIOA BioAge Labs, Inc. 72% Reciprocal relationship from BIOA graph: Reciprocal relationship from GPCR graph: Reciprocal relationship from BIOA graph: Reciprocal relationship from GPCR graph: Reciprocal relationship from BIOA g…
SDGR Schrödinger, Inc. 72% Reciprocal relationship from SDGR graph: inical trials, and the results of our clinical trials may not satisfy the requirements of the U.S. Food and Drug Administration or other comparable foreign re…
SNYNF Sanofi 72% ould lead to ineffective product or target candidates and exposure to competitive and reputational harm. We face increased competition from other companies that are using AI and related methods for d…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from GPCR graph: ould lead to ineffective product or target candidates and exposure to competitive and reputational harm. We face inc…
VKTX Viking Therapeutics, Inc. 72% Reciprocal relationship from VKTX graph: Reciprocal relationship from GPCR graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from GPCR graph: Reciprocal relationship from VKTX g…
ACONCAGUA-BIO-INC ACONCAGUA-BIO-INC 62% rrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our structure-based drug discovery platform or our product cand…
ANNAPURNA-BIO-PTY-LIMITED ANNAPURNA-BIO-PTY-LIMITED 62% S Antibodies; and myelin restoration and neuroinflammation by Contineum Therapeutics. Many of our competitors, either alone or with their collaborators, have significantly greater financial, technica…
BASECAMP-BIO-INC BASECAMP-BIO-INC 62% mpany determined that at inception the transaction price was $ 100.0 million which consisted of fixed consideration of $ 100.0 million represented by the upfront payment. The transaction price was re…
ELI-LILLY-JIANGSU-HANSOH-PHARMACEUTICAL-GROUP ELI-LILLY-JIANGSU-HANSOH-PHARMACEUTICAL-GROUP 62% ould lead to ineffective product or target candidates and exposure to competitive and reputational harm. We face increased competition from other companies that are using AI and related methods for d…
GASHERBRUM-BIO-PTY-LIMITED GASHERBRUM-BIO-PTY-LIMITED 62% S Antibodies; and myelin restoration and neuroinflammation by Contineum Therapeutics. Many of our competitors, either alone or with their collaborators, have significantly greater financial, technica…
INNOVENT-BIOLOGICS-PEGBIO-METAVIA-THERAPEUTICS-H INNOVENT-BIOLOGICS-PEGBIO-METAVIA-THERAPEUTICS-H 62% ould lead to ineffective product or target candidates and exposure to competitive and reputational harm. We face increased competition from other companies that are using AI and related methods for d…
INNOVENT-BIOLOGICS-PEGBIO-NEUROBO-PHARMACEUTICAL INNOVENT-BIOLOGICS-PEGBIO-NEUROBO-PHARMACEUTICAL 62% ould lead to ineffective product or target candidates and exposure to competitive and reputational harm. We face increased competition from other companies that are using AI and related methods for d…
LEERINK-PARTNERS-LLC LEERINK-PARTNERS-LLC 62% ts We have no products approved for commercial sale and have not generated any revenue to date, and we continue to incur significant research and development and other expenses related to our ongoing…
LHOTSE-BIO-INC LHOTSE-BIO-INC 62% rrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our structure-based drug discovery platform or our product cand…
ROCHE-GROUP ROCHE-GROUP 62% ould lead to ineffective product or target candidates and exposure to competitive and reputational harm. We face increased competition from other companies that are using AI and related methods for d…

Structure Therapeutics Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
GPCR-DEBT Debt stack $6.5M 90% Market cache reports total debt of $6.5M.
GPCR-DEBT-9857 Xbrl Convertible 90% xbrl convertible detail from xbrl 2023-12-31.

Structure Therapeutics Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Structure Therapeutics Inc..

Structure Therapeutics Inc. Ownership

HolderNameConfidenceEvidence
GPCR-OWNER-AVORO-CAPITAL-ADVISORS-LLC Avoro Capital Advisors LLC 90% 13F overlay lists Avoro Capital Advisors LLC as top holder; 198 tracked holders.

Structure Therapeutics Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
EDIT Editas Medicine, Inc. 100.00 2
BBIO BridgeBio Pharma, Inc. 100.00 2
LGND Ligand Pharmaceuticals Incorporated 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
DBVTF DBV TECHNOLOGIES 100.00 2
SVA Sinovac Biotech Ltd. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
BIOA BioAge Labs, Inc. 100.00 1 ['customer']
CYTK Cytokinetics, Incorporated 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
CRBP Corbus Pharmaceuticals Holdings, Inc. 100.00 1 ['supplier']
CCEP Coca-Cola Europacific Partners PLC 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
AZN AstraZeneca PLC 100.00 2
CLDX Celldex Therapeutics, Inc. 100.00 2
BCYC Bicycle Therapeutics plc 100.00 2
ATOS Atossa Therapeutics, Inc. 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Structure Therapeutics Inc..

Unlock full GPCR data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
GPCR
Unlock GPCR Supply Chain Data
Verified relationships include:
SCHR-DINGERSCHR-DINGERSupplier92%
GENENTECHGENENTECHSupplier90%
F-HOFFMANN-LA-ROCHE-LTDF-HOFFMANN-LA-ROCHE-LTDCustomer92%
GENENTECH-INCGENENTECH-INCCustomer92%
+26 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →